全文获取类型
收费全文 | 41893篇 |
免费 | 1196篇 |
国内免费 | 313篇 |
专业分类
耳鼻咽喉 | 371篇 |
儿科学 | 814篇 |
妇产科学 | 590篇 |
基础医学 | 6290篇 |
口腔科学 | 585篇 |
临床医学 | 3344篇 |
内科学 | 7151篇 |
皮肤病学 | 870篇 |
神经病学 | 4430篇 |
特种医学 | 2046篇 |
外科学 | 5414篇 |
综合类 | 1991篇 |
一般理论 | 36篇 |
预防医学 | 2270篇 |
眼科学 | 662篇 |
药学 | 3518篇 |
28篇 | |
中国医学 | 81篇 |
肿瘤学 | 2911篇 |
出版年
2023年 | 203篇 |
2022年 | 482篇 |
2021年 | 1082篇 |
2020年 | 736篇 |
2019年 | 1050篇 |
2018年 | 1720篇 |
2017年 | 1130篇 |
2016年 | 1624篇 |
2015年 | 1766篇 |
2014年 | 2097篇 |
2013年 | 2726篇 |
2012年 | 2703篇 |
2011年 | 2128篇 |
2010年 | 2074篇 |
2009年 | 1794篇 |
2008年 | 2094篇 |
2007年 | 2129篇 |
2006年 | 2090篇 |
2005年 | 2064篇 |
2004年 | 1805篇 |
2003年 | 1598篇 |
2002年 | 1444篇 |
2001年 | 340篇 |
2000年 | 374篇 |
1999年 | 453篇 |
1998年 | 499篇 |
1997年 | 407篇 |
1996年 | 312篇 |
1995年 | 232篇 |
1994年 | 253篇 |
1993年 | 220篇 |
1992年 | 154篇 |
1991年 | 173篇 |
1990年 | 171篇 |
1989年 | 157篇 |
1988年 | 159篇 |
1987年 | 110篇 |
1986年 | 105篇 |
1985年 | 106篇 |
1984年 | 121篇 |
1983年 | 93篇 |
1982年 | 123篇 |
1981年 | 105篇 |
1980年 | 98篇 |
1979年 | 71篇 |
1977年 | 77篇 |
1976年 | 81篇 |
1974年 | 65篇 |
1955年 | 66篇 |
1954年 | 63篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Hui-Ju Ch’ang 《World journal of hepatology》2015,7(16):2029-2040
The success of sorafenib in prolonging survival of patients with hepatocellular carcinoma (HCC) makes therapeutic inhibition of angiogenesis a component of treatment for HCC. To enhance therapeutic efficacy, overcome drug resistance and reduce toxicity, combination of antiangiogenic agents with chemotherapy, radiotherapy or other targeted agents were evaluated. Nevertheless, the use of antiangiogenic therapy remains suboptimal regarding dosage, schedule and duration of therapy. The issue is further complicated by combination antiangiogenesis to other cytotoxic or biologic agents. There is no way to determine which patients are most likely respond to a given form of antiangiogenic therapy. Activation of alternative pathways associated with disease progression in patients undergoing antiangiogenic therapy has also been recognized. There is increasing importance in identifying, validating and standardizing potential response biomarkers for antiangiogenesis therapy for HCC patients. In this review, biomarkers for antiangiogenesis therapy including systemic, circulating, tissue and imaging ones are summarized. The strength and deficit of circulating and imaging biomarkers were further demonstrated by a series of studies in HCC patients receiving radiotherapy with or without thalidomide. 相似文献
4.
5.
6.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
7.
Stephan Koter Tina U. Cohnert Korbinian B. Hindermayr Jörg Lindenmann Maximilian Brückner Wolfgang K. Oswald Georg Werkgartner Doris Wagner 《Journal of vascular surgery》2019,69(4):1227-1232
Objective
Low psoas muscle area is shown to be an indicator for worse postoperative outcome in patients undergoing vascular surgical. Additionally, it has been associated with longer durations of hospital stay in patients with cancer who undergo surgery and subsequently greater health care costs in Europe and the United States. We sought to evaluate this effect on hospital expenditure for patients undergoing vascular repair in a health care system with universal access.Methods
Skeletal muscle mass was assessed on preoperative abdominal computed tomography scans of patients undergoing open aortic aneurysm repair in a retrospective fashion. The skeletal muscle index (SMI) was used to define low muscle mass. Health care costs were obtained for all patients and the relationship between a low SMI and higher costs was explored using linear regression and cross-sectional analysis.Results
We included 156 patients (81.5% male) with a median age of 72 years undergoing elective surgery for infrarenal abdominal aortic aneurysm in this analysis. The median SMI for patients with low skeletal muscle mass was 53.21 cm2/kg and for patients without, 70.07 cm2/kg. Hospital duration of stay was 2 days longer in patients with low skeletal muscle mass as compared with patients with normal (14 days vs 11 days; P = .001), as was duration of intensive care stay (3 days vs 1 day; P = .01). The median overall hospital costs were €10,460 higher for patients with a low SMI as compared with patients with a normal physical constitution (€53,739 [interquartile range, €45,007-€62,471] vs €43,279 [interquartile range, €39,509-€47,049]; P = .001). After confounder adjustment, a low SMI was associated with a 14.68% cost increase in overall hospital costs, for a cost increase of €6521.Conclusions
Low skeletal muscle mass is independently associated with higher hospital as well as intensive care costs in patients undergoing elective aortic aneurysm repair. Strategies to reduce this risk factor are warranted for these patients. 相似文献8.
9.
10.